The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

Society of Toxicology 2010 Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). Tungsten-Carbide Cobalt.................. 271 Type I Hypersensitivity..................... 302 Type II cartilage.............................. 1142 Tyrosine Hydroxylase..................... 1271 tyrosine kinase inhibitors.................... 79 U.S. Food.......................................... 641 Ubiquitin......................................... 1822 UCP-2............................................. 1269 UDP-glucoronosyltransferase......... 1234 Ultrafine Particles........................... 1477 Ultrastructure........................ 1154, 1292 uncertainty.............................. 896, 1925 uncertainty analysis.......................... 545 uncertainty factor.................. 1911, 1913 undergraduate research................... 2083 Unfolded Protein Response............ 1631 United States................................... 1149 uranium............................................. 577 Urea cycle......................................... 221 urinary biomarkers........ 582, 1323, 1895 Urinary Cadmium........................... 1821 Urine biomarkers............................ 1864 Uroepithelial..................................... 492 urogenital sinus................................. 844 urothelium......................................... 955 UROtsa..................................... 953, 954 Usnic acid....................................... 1960 Usual intake.................................... 1869 uterine receptivity............................. 416 Utrasonic Vocalizations.................... 862 UV...................................... 82, 241, 714 UVA.................................................. 693 UVB................................................ 1671 Vaccine................................. 1370, 1373 Vaccine immunogenicity.................. 409 vaccine safety assessment............... 1054 Vaccines..................... 1368, 1369, 1371, 1372, 1439 vaginal irritation............................... 109 vaginal irritation testing............ 412, 491 Valerian Root.................................. 1040 validation.............. 101, 908, 1808, 2217 validation study........... 2109, 2110, 2111 valproate................................. 161, 1059 Valproic Acid.................................. 1581 Vanadium.................... 1945, 2167, 2168 vanilloid/capsaicin................ 2016, 2153 Vanin-1........................................... 2131 vapor................................................. 493 vapor exposure................................ 1022 Variability......................... 98, 896, 2012 vascular damage............................. 1310 Vascular injury................................ 1746 Vascular physiology........................ 1509 vascular remodeling.......................... 576 Vasculitis............................... 1746, 2186 VCAM-1......................................... 1748 VCD.................................................. 387 VDBP............................................. 1305 vegetative insecticidal protein........ 1180 VEGF.............................................. 1734 VEGFR................................. 1084, 1734 vehicle-effects................................. 1184 vesicant............................... 67, 343, 347 Vestibular system............................ 1253 vinyl acetate.................................... 1112 Vinylcyclohexene............................... 28 Vinylphenol...................................... 443 Viracept............................................. 551 Virtual............................................. 1387 Virtual Liver................ 1407, 2080, 2081 virus................................................ 1532 Visual analytics................................. 883 vitamin D........................................ 1045 Vitamins............................................ 609 vitellogenin....................................... 912 VLCAD............................................ 462 VOC................................................ 1258 VOCs.................................... 1041, 1579 Volatile Organic Compounds.......... 1301 Von Willebrand Factor.................... 1577 VRP................................................ 2186 VX.................................................... 342 Waste sites........................................ 246 Water Quality.................................. 1940 Weight of Evidence........................ 1179 welding fume.................................... 734 Welding fumes.................................... 21 Werner syndrome protein................. 677 Whole Embryo Culture..... 404, 829, 836 Whole Life........................................ 965 Wildfire............................................. 776 Wistar rat.......................................... 913 Wnt signalling................................ 1433 Women’s Health............................. 1004 woodsmoke..................................... 1801 Wound Healing................................. 343 wound healing model....................... 483 X-radiation........................................ 394 xenobiotic exposure........................ 2010 xenobiotic metabolism......... 1928, 2012, 2128 xenobiotics................................ 10, 1416 xenoestrogens................................. 2105 Xenopus............................................ 426 XOMA 052..................................... 1043 XPA(-/-)p53(+/-) mice...................... 131 XPC........................................ 361, 2009 XPC Lys939Gln and XRCC1 Arg399Gln polymorphisms.............. 529 XRF................................................ 2118 Y-H2AX.............................................. 66 Yaupon.............................................. 748 yeast................................ 224, 722, 1845 yolk sac............................................. 836 Zebrafish.................. 85, 86, 87, 90, 165, 172, 414, 425, 440, 463, 466, 467, 680, 681, 682, 684, 685, 850, 1127, 1390, 1412, 1706, 1843, 2023, 2024, 2025, 2027, 2028, 2065 Zidovudine........................................ 703 zinc... 146, 786, 1362, 1363, 1364, 1366 zinc bisglycinate chelate................. 2172 zinc finger nuclease.......................... 904 zinc nanoparticles................. 2067, 2068 zinc-sensing.................................... 1670 Ziram.............................................. 1239 ZnO................................................... 265 Zucker............................................... 555 Zymogen Granules......................... 1077 Key Word Index SOT 2010 Annual Meeting 507
The Official Journal of the Society of Toxicology toxicological sciences Impact Factor of 4.443!* Ranked in the top 5 most-cited journals in Toxicology! www.toxsci.oxfordjournals.org visit our booth at toxexpo 2010 for a free sample copy *ISI Journal Citation Reports 2008 Edition, published in 2009
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIOLOGICAL PATHWAY ANALYSIS: AN I
Page 7 and 8:
11 ICH INITIATIVES FOR CONDUCTING P
Page 9 and 10:
models. Experimental approaches and
Page 11 and 12:
30 SILICA AND ASBESTOS IMMUNOTOXICI
Page 13 and 14:
40 NONCANCER TOXICITY POTENTIAL AT
Page 15 and 16:
ased products for patient administr
Page 17 and 18:
nase regulates Hsp27-induced reorga
Page 19 and 20:
exposure resulted in splenomegaly.
Page 21 and 22:
We investigated the effect of imati
Page 23 and 24:
well plate prevented free cell move
Page 25 and 26:
98 DERIVING SIGNATURES OF IN VIVO T
Page 27 and 28:
sulfate, cinnamic aldehyde, 2,4-din
Page 29 and 30:
The final product will be a system
Page 31 and 32:
mercially available STP brands by m
Page 33 and 34:
for six weeks, with 10 mg/kg azoxym
Page 35 and 36:
eceived RES post-TCDD exposure when
Page 37 and 38:
morigenesis. Knocking down of JARID
Page 39 and 40:
163 MICROPET IMAGING OF [18F]-DFNSH
Page 41 and 42:
These results are comparable to tha
Page 43 and 44:
activity as assessed by lever press
Page 45 and 46:
for measured physico-chemical param
Page 47 and 48:
199 DEVELOPMENT OF A MULTIPARAMETER
Page 49 and 50:
To cause PLD, a drug needs to enter
Page 51 and 52:
In contrast to the parent PBDEs and
Page 53 and 54:
transiently transfected HEK 293 cel
Page 55 and 56:
TCDD exposure, 24 h prior to a 20 %
Page 57 and 58:
244 NON-ADDITIVE EFFECTS OF PCB153
Page 59 and 60:
253 COMPARISON OF MIXTURE TOXICITY
Page 61 and 62:
two cerium oxide nanoparticles of v
Page 63 and 64:
271 SIZE-DEPENDENT EFFECTS OF TUNGS
Page 65 and 66:
adigms such as Tox 21 and Toxcast,
Page 67 and 68:
QDs with emission maximum at 800nm
Page 69 and 70:
Cleveland, while others were found
Page 71 and 72:
without the need of animal testing.
Page 73 and 74:
Conclusions: These results are cons
Page 75 and 76:
ing oxime reactivation and organoph
Page 77 and 78:
335 A NON-OXIME IMPROVES SURVIVAL I
Page 79 and 80:
alties suffer from permanent lung i
Page 81 and 82:
ies have established inflammatory b
Page 83 and 84:
363 GENETIC VARIATION IN ISOGENIC M
Page 85 and 86:
372 EVALUATING THE BIOLOGICAL INTER
Page 87 and 88:
dose of 1/20 LD50 (400 mg/kg.bwt) f
Page 89 and 90:
median CR-adjusted isoflavone conce
Page 91 and 92:
data indicate that AhR deletion pro
Page 93 and 94:
February 2006). The rabbit is one o
Page 95 and 96:
tal neurotoxicity (DNT) test (OECD
Page 97 and 98:
of selected microorganisms that are
Page 99 and 100:
BVI. Histopathological analysis was
Page 101 and 102:
446 MOLECULAR CLONING AND CHARACTER
Page 103 and 104:
portant in predicting risk. CYPs 1A
Page 105 and 106:
ats, which involves metabolic activ
Page 107 and 108:
473 BOVINE CORNEAL OPACITY AND PERM
Page 109 and 110:
482 TYPE III DEIODINASE (D3) IS PRO
Page 111 and 112:
tancy evaluation and ranking of bat
Page 113 and 114:
501 CHARACTERIZATION OF ESTERASE, G
Page 115 and 116:
510 REDOX CYCLING BY ENDOGENOUS 2-
Page 117 and 118:
prostate cancer cells. All 8 BEL de
Page 119 and 120:
metallic nickel nanoparticles. Acti
Page 121 and 122:
variety of more or less reactive ch
Page 123 and 124:
550 QUALIFICATION STRATEGIES-GENOTO
Page 125 and 126:
ferentiation, and 3) how mixtures o
Page 127 and 128:
572 LOW-CHRONIC ARSENIC EXPOSURE: E
Page 129 and 130:
582 IDENTIFICATION OF SENSITIVE URI
Page 131 and 132:
duced by the genetic outcross of fe
Page 133 and 134:
fects of new compounds are equally
Page 135 and 136:
acterize the current state of the s
Page 137 and 138:
620 CHARACTERIZATION OF POTENTIAL I
Page 139 and 140:
ways. Moreover, both MAP kinase and
Page 141 and 142:
641 POPS IN THE U.S. POPULATION AND
Page 143 and 144:
studies such as the NCS, consider h
Page 145 and 146:
the beginning of the academic caree
Page 147 and 148:
trophil infiltration, a significant
Page 149 and 150:
tactic response and optokinetic res
Page 151 and 152:
usually high spontaneous PIG-A MFs.
Page 153 and 154:
699 PROMUTAGEN ACTIVATION AND P450
Page 155 and 156:
oxodG in bone marrow, spleen, kidne
Page 157 and 158:
718 GENOTOXICITY OF ORGANIC EXTRACT
Page 159 and 160:
ment were 18.0 and 4.5 nM for BEAS-
Page 161 and 162:
strongest activation of nuclear fac
Page 163 and 164:
746 MACROPHAGE INHIBITORY CYTOKINE-
Page 165 and 166:
screening of cell migration. High-c
Page 167 and 168:
dase inhibition). In contrast, inhi
Page 169 and 170:
mice; the decrease was more pronoun
Page 171 and 172:
Markers of oxidative damage reached
Page 173 and 174:
793 PULMONARY RESPONSE, OXIDATIVE S
Page 175 and 176:
cilitate clinical and industrial ap
Page 177 and 178:
sion of p-p38, p-p53, p21 and cycli
Page 179 and 180:
821 KIDNEY INJURY MOLECULE-2 GENE D
Page 181 and 182:
commercial applications, and have b
Page 183 and 184:
developmental effects. The residual
Page 185 and 186:
strand breaks in an in vitro model
Page 187 and 188:
etate (immunotoxicity). 2,4-D was t
Page 189 and 190:
867 MELATONIN AMELIORATES CYCLOPHOS
Page 191 and 192:
pharmacokinetic (PBPK) models. Ten
Page 193 and 194:
of radiolabeled Mn (carrier-free 54
Page 195 and 196:
893 UNVEILING ASSOCIATIONS BETWEEN
Page 197 and 198:
using area under the concentration
Page 199 and 200:
912 COMMERCIAL FISH DIETS INDUCE VI
Page 201 and 202:
922 A STUDY OF PHOTOTOXICITY FOLLOW
Page 203 and 204:
from 0.1 to 2.9 g/L (saturated vapo
Page 205 and 206:
vasive method for assessing several
Page 207 and 208:
950 ARSENITE DOWN-REGULATES THE CAR
Page 209 and 210:
inflammatory signaling is altered b
Page 211 and 212:
treated wood. Seventy-five of 132 w
Page 213 and 214:
ergy homeostasis and raising levels
Page 215 and 216:
treated with mercury and then with
Page 217 and 218:
997 IN VIVO CORRELATES OF THE MANGA
Page 219 and 220:
of the panel. The panel was compris
Page 221 and 222:
sponse, location, and severity scor
Page 223 and 224:
tant source of n-3 fatty acids such
Page 225 and 226:
old for serious, irreversible or es
Page 227 and 228:
1045 SUBCHRONIC TOXICITY EVALUATION
Page 229 and 230:
sites collected 3 days after inject
Page 231 and 232:
1063 MOLECULAR MECHANISM OF OLANZAP
Page 233 and 234:
esponses, and can be available for
Page 235 and 236:
hence more physiologically relevant
Page 237 and 238:
thesized apoproteins, so we tested
Page 239 and 240:
vate CYP3A5 but could be released b
Page 241 and 242:
1108 STYRENE-INDUCED TOXIC EFFECTS
Page 243 and 244:
1118 THE PRESENCE OF DIETHYL FUMARA
Page 245 and 246:
zebrafish cells were first exposed
Page 247 and 248:
utene-1,4-dial, which has been show
Page 249 and 250:
groups, largely due to lower non-HD
Page 251 and 252:
Exposure to gluten in individuals w
Page 253 and 254:
contrast to VGSC activators such as
Page 255 and 256:
1175 70% HYDROFLUORIC ACID (HF) CUT
Page 257 and 258:
axis. An increase in hyaline drople
Page 259 and 260:
1194 esiRNA AND siRNA HIGH-THROUGHP
Page 261 and 262:
1203 ARYL HYDROCARBON RECEPTOR-DNA
Page 263 and 264:
permeability (calcein), mitochondri
Page 265 and 266:
olytic caspase activation, caspase-
Page 267 and 268:
teristics of a human T-type voltage
Page 269 and 270:
80% of the activity from the yellow
Page 271 and 272:
1251 DEVELOPMENTAL EXPOSURE TO DELT
Page 273 and 274:
1260 MANEB ENHANCES MPP + -INDUCED
Page 275 and 276:
demonstrated by knockdown of beclin
Page 277 and 278:
1278 PINK1 AND MITOCHONDRIAL DYNAMI
Page 279 and 280:
treatment for number of live worms.
Page 281 and 282:
1297 INVESTIGATION OF THE NEUROTOXI
Page 283 and 284:
1306 DEVELOPMENT OF AN IN VITRO ASS
Page 285 and 286:
1315 EVALUATION OF 3- AND 1-METHYLH
Page 287 and 288:
prior to kainic acid-induced seizur
Page 289 and 290:
1334 AFFECT OF GENETIC VARIATION ON
Page 291 and 292:
1346 THE OTHER WORLD OF THE TRANSCR
Page 293 and 294:
strate, leading to excess microvesi
Page 295 and 296:
1368 OVERVIEW OF THERAPEUTIC VACCIN
Page 297 and 298:
to a bovine adrenal cortical epithe
Page 299 and 300:
DOTC had no effects. These results
Page 301 and 302:
1398 PULMONARY TOXICITY OF CERIUM D
Page 303 and 304:
PPARα, LXR, ER, AR and AhR activit
Page 305 and 306:
1417 MECHANISM OF GENDER-DIVERGENT
Page 307 and 308:
els, they disrupt homeostatic contr
Page 309 and 310:
were to characterize exposure of th
Page 311 and 312:
1448 ADVERSE OUTCOME PATHWAYS AND E
Page 313 and 314:
the level in urine was 25% of the m
Page 315 and 316:
1;akt-2 double mutant and pdk-1 mut
Page 317 and 318:
jury effects when compared to contr
Page 319 and 320:
tude than equivalent oral doses. Af
Page 321 and 322:
cells; and increased iNOS and MCP-1
Page 323 and 324:
B6.Cg-Kit W-sh mice. These findings
Page 325 and 326:
1511 STATIN-TREATMENT EFFECTIVELY R
Page 327 and 328:
1520 EFFECT OF INHALATION EXPOSURE
Page 329 and 330:
numbers of IFN-γ producing cells w
Page 331 and 332:
These data indicate that TCDD treat
Page 333 and 334:
esponse to allogenic cells, where P
Page 335 and 336:
larly suppressed LPS-induced TNF-α
Page 337 and 338:
1565 INFLUENCE OF EXPOSURE ROUTE AN
Page 339 and 340:
veloping animals to adverse effects
Page 341 and 342:
the observed CL values were 0.07 L/
Page 343 and 344:
which is most relevant for potentia
Page 345 and 346:
tive impairment, suggesting that ox
Page 347 and 348:
1611 AN IN VITRO METABOLOMICS APPRO
Page 349 and 350:
Expression of the β6 integrin (Itg
Page 351 and 352:
ats (10 μg/kg TCDD). Here we repor
Page 353 and 354:
at liver slices and how the metabon
Page 355 and 356:
with gender differences in AUC and
Page 357 and 358:
oxetine (30 mg/kg reduced to 15 mg/
Page 359 and 360:
eleased from necrotic cells where i
Page 361 and 362:
plants, they are present in surface
Page 363 and 364:
ferentiation (quantitative in-cell
Page 365 and 366:
control for macrophage activation).
Page 367 and 368:
to 0.5μg/ml. Minimal inhibitory co
Page 369 and 370:
lines tested. Given that dex and AT
Page 371 and 372:
tion in the absence of an immune re
Page 373 and 374:
treated rats had lower calcium load
Page 375 and 376:
1740 PROFILING COMPOUNDS WITH CARDI
Page 377 and 378:
dothelial cells confirmed caveolin-
Page 379 and 380:
1758 GINKGO BILOBA EXTRACT INDUCES
Page 381 and 382:
arin-induced suppression of MDR1 ex
Page 383 and 384:
1780 ANTIANDROGENIC AND ANTIPROLIFE
Page 385 and 386:
included in the evaluation, most of
Page 387 and 388:
1799 GUIDANCE ON THE APPLICATION OF
Page 389 and 390:
However, substances with EC3 values
Page 391 and 392:
1816 CD-INDUCED EGFR TRANSACTIVATIO
Page 393 and 394:
1826 KERATIN 7 EXPRESSION IN INDEPE
Page 395 and 396:
centa were collected at the time of
Page 397 and 398:
1845 SYSTEMATIC SCREENING OF YEAST
Page 399 and 400:
underlying the development of co-mo
Page 401 and 402:
eing measured in experimental roden
Page 403 and 404:
ufactured in the US for more than 3
Page 405 and 406:
nine (N7-THB-Gua) and N7-hydroxyphe
Page 407 and 408:
1892 EFFECT OF LAMBDA-CYHALOTHRIN O
Page 409 and 410:
22 in Phase I. Antimicrobial pestic
Page 411 and 412:
kinetic and dynamic differences, an
Page 413 and 414:
iphenyl, saccharin and melamine was
Page 415 and 416:
1930 DEVELOPMENT OF A RELATIVE SOUR
Page 417 and 418:
1939 MODE OF ACTION FOR THE CANCER
Page 419 and 420:
human was about 1.5-fold lower (60
Page 421 and 422:
Disruption of BDEC integrity in alp
Page 423 and 424:
1968 A HUMAN HEPG2 LUCIFERASE ASSAY
Page 425 and 426:
in the offspring during tumor devel
Page 427 and 428:
een developed to investigate perfus
Page 429 and 430:
to 131.73 μg/mL for KLH-specific I
Page 431 and 432:
cell lines (ATCC) were cultured in
Page 433 and 434:
flammation and xenobiotic metabolis
Page 435 and 436:
vide many contributions: with its g
Page 437 and 438:
to-metal joint replacement. For exa
Page 439 and 440:
to be addressed or negotiated. Deci
Page 441 and 442:
especially with anti-TNF therapies.
Page 443 and 444:
genic line Tg(are:eGFP) was created
Page 445 and 446:
2074 COMPUTATIONAL ASSESSMENT OF TH
Page 447 and 448:
2084 INHIBITION OF 11β-HSD1 DECREA
Page 449 and 450:
(T) and express several enzymes inv
Page 451 and 452:
2101 GENISTEIN MODULATION OF BLOOD
Page 453 and 454:
males per group were dosed orally o
Page 455 and 456:
ate the feasibility of assessing re
Page 457 and 458:
changed. Hepatic protein carbonyl l
Page 459 and 460:
sought to examine alterations in he
Page 461 and 462:
2147 A SINGLE AMINO ACID CONTROLS T
Page 463 and 464:
Gstm7) was independent of both CAR
Page 465 and 466:
ility of tungsten trioxide (WO3), t
Page 467 and 468:
ured by real-time PCR array and rel
Page 469 and 470:
glucose, and creatinine levels, and
Page 471 and 472:
Several studies have reported suppr
Page 473 and 474:
exposure between TCDD-exposed labor
Page 475 and 476:
Furthermore, with increasing number
Page 477 and 478:
Society of Toxicology 2010 Author I
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496: Society of Toxicology 2010 Author I
Page 501 and 502: Society of Toxicology 2010 Abstract
Page 513 and 514: 49 th Annual Meeting and ToxExpo A
Page 545: 49 th Annual Meeting and ToxExpo A
show all

The Toxicologist - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?